BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, Mcalindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: ACR GUIDELINE FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS PREVENTION AND TREATMENT. Arthritis & Rheumatology 2017;69:1521-37. [DOI: 10.1002/art.40137] [Cited by in Crossref: 197] [Cited by in F6Publishing: 140] [Article Influence: 39.4] [Reference Citation Analysis]
Number Citing Articles
1 Di Matteo S, Di Meo C, Carpino G, Zoratto N, Cardinale V, Nevi L, Overi D, Costantini D, Pinto C, Montanari E, Marzioni M, Maroni L, Benedetti A, Viola M, Coviello T, Matricardi P, Gaudio E, Alvaro D. Therapeutic effects of dexamethasone-loaded hyaluronan nanogels in the experimental cholestasis. Drug Deliv Transl Res 2022. [PMID: 35226290 DOI: 10.1007/s13346-022-01132-7] [Reference Citation Analysis]
2 Charoenngam N. Vitamin D and Rheumatic Diseases: A Review of Clinical Evidence. Int J Mol Sci 2021;22:10659. [PMID: 34639000 DOI: 10.3390/ijms221910659] [Reference Citation Analysis]
3 Kobza AO, Herman D, Papaioannou A, Lau AN, Adachi JD. Understanding and Managing Corticosteroid-Induced Osteoporosis. Open Access Rheumatol 2021;13:177-90. [PMID: 34239333 DOI: 10.2147/OARRR.S282606] [Reference Citation Analysis]
4 Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Panicker J. The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis. Clin Rheumatol 2021;40:725-34. [PMID: 32681366 DOI: 10.1007/s10067-020-05294-y] [Reference Citation Analysis]
5 Jia R, Liu N, Zhu Y, Li Q, Li W. Curative Effect of Prebiotics/Probiotics Preparations Combined with Zoledronic Acid + Calcitriol Regimen on Patients with Primary Osteoporosis and Their Influences on Bone Metabolism Markers. Emergency Medicine International 2022;2022:1-7. [DOI: 10.1155/2022/3293362] [Reference Citation Analysis]
6 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
7 Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy. Endocr Rev 2018;39:519-48. [PMID: 29905835 DOI: 10.1210/er.2018-00097] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 20.3] [Reference Citation Analysis]
8 Hsu E, Nanes M. Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 2017;24:411-7. [PMID: 28857847 DOI: 10.1097/MED.0000000000000368] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 4.8] [Reference Citation Analysis]
9 Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers 2020;6:7. [PMID: 31974366 DOI: 10.1038/s41572-019-0141-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]
10 Rodrigues JC, Walsh M. Risks and Benefits of Glucocorticoids in ANCA-Associated Vasculitis. Curr Treat Options in Rheum 2017;3:244-53. [DOI: 10.1007/s40674-017-0081-z] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 van Bodegraven AA, Bravenboer N. Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int 2020;31:637-46. [PMID: 31822927 DOI: 10.1007/s00198-019-05234-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
12 Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. JCO 2019;37:2916-46. [DOI: 10.1200/jco.19.01696] [Cited by in Crossref: 35] [Cited by in F6Publishing: 11] [Article Influence: 11.7] [Reference Citation Analysis]
13 Tayer-Shifman OE, Bingham KS, Touma Z. Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management. Drugs Aging 2021. [PMID: 34913146 DOI: 10.1007/s40266-021-00911-0] [Reference Citation Analysis]
14 Clare S, Dash A, Liu Y, Harrison J, Vlastaris K, Waldman S, Griffin R, Cooke P, Vad V, Casey E, Bockman RS, Lane J, McMahon D, Stein EM. Epidural Steroid Injections Acutely Suppress Bone Formation Markers in Postmenopausal Women. J Clin Endocrinol Metab 2022:dgac287. [PMID: 35524754 DOI: 10.1210/clinem/dgac287] [Reference Citation Analysis]
15 Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Müller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers 2019;5:45. [PMID: 31273209 DOI: 10.1038/s41572-019-0096-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 71] [Article Influence: 30.3] [Reference Citation Analysis]
16 Agarwal A, Adachi JD. Therapies for Preventing Bone Loss with Glucocorticoid Treatment. Curr Osteoporos Rep 2021;19:34-9. [PMID: 33409989 DOI: 10.1007/s11914-020-00653-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nam SW, Sung YK, Kim D, Cho SK, Song Y, Choi YY, Sim Y, Kim TH. The usefulness of trabecular bone score in patients with ankylosing spondylitis. Korean J Intern Med 2021;36:1211-20. [PMID: 32599681 DOI: 10.3904/kjim.2020.065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Shaharir SS, Chua SH, Mohd R, Mustafar R, Noh MM, Shahril NS, Said MSM, Rajalingham S. Risk factors for symptomatic Avascular Necrosis (AVN) in a multi-ethnic Systemic Lupus Erythematosus (SLE) cohort. PLoS One 2021;16:e0248845. [PMID: 33739994 DOI: 10.1371/journal.pone.0248845] [Reference Citation Analysis]
19 So J, Mok CC. Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab. Journal of Clinical Rheumatology and Immunology 2020;20:71-9. [DOI: 10.1142/s2661341720300074] [Reference Citation Analysis]
20 Kassardjian C, Widdifield J, Paterson JM, Kopp A, Nagamuthu C, Barnett C, Tu K, Breiner A. Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study. J Neuromuscul Dis 2021;8:625-32. [PMID: 33554923 DOI: 10.3233/JND-200612] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cardet JC, Bulkhi AA, Lockey RF. Nonrespiratory Comorbidities in Asthma. J Allergy Clin Immunol Pract 2021;9:3887-97. [PMID: 34492402 DOI: 10.1016/j.jaip.2021.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sato H, Kondo N, Takai C, Kurosawa Y, Hasegawa E, Wakamatsu A, Kobayashi D, Nakatsue T, Abe A, Kazama JJ, Kuroda T, Ito S, Ishikawa H, Endo N, Narita I. The Risks of Femoral Localized Periosteal Thickening in Patients with Autoimmune Inflammatory Rheumatic Diseases. Mod Rheumatol 2022:roac062. [PMID: 35715985 DOI: 10.1093/mr/roac062] [Reference Citation Analysis]
23 Dimitri D, Echaniz-Laguna A, Mariette X. Risedronate-induced rhabdomyolysis in a patient with inflammatory myopathy. Joint Bone Spine 2021;88:105090. [PMID: 33147494 DOI: 10.1016/j.jbspin.2020.105090] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Hattori K, Hirano Y, Kojima T. Predictors of glucocorticoid‐free remission in patients with polymyalgia rheumatica treated with prednisolone. Int J Rheum Dis 2020;23:1581-6. [DOI: 10.1111/1756-185x.13978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis Rheumatol 2019;71:1174-84. [PMID: 30816640 DOI: 10.1002/art.40874] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 15.7] [Reference Citation Analysis]
26 Cetin B, Cetin EA, Arikan H, Velioglu A, Alibaz-Oner F, Direskeneli H, Tuglular S, Asicioglu E. FRAX scores are increased in patients with ANCA-associated vasculitis. Int Urol Nephrol 2021. [PMID: 33884566 DOI: 10.1007/s11255-021-02857-z] [Reference Citation Analysis]
27 Cerdas Pérez S, Herrera LE, González E. Clinical impact of misinterpretation of dual-energy X-ray absorptiometry during the evaluation of osteoporotic patients. Climacteric 2021;:1-10. [PMID: 34008476 DOI: 10.1080/13697137.2021.1918079] [Reference Citation Analysis]
28 Khoury P, Bochner BS. Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options. J Allergy Clin Immunol Pract 2018;6:1446-53. [PMID: 30197068 DOI: 10.1016/j.jaip.2018.04.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
29 Mettawi AS, Soliman SS, Taha ME. Clinician's guide for the management and research of osteoporosis in North African men: a guidelines comparison, a cost-effectiveness analysis, and a local algorithm. Arch Osteoporos 2020;15:159. [PMID: 33037516 DOI: 10.1007/s11657-020-00830-4] [Reference Citation Analysis]
30 Valladales-restrepo LF, Vargas-diaz K, Peña-verjan NM, Jaramillo-sepúlveda S, Machado-alba JE. Pharmacological management, and potentially inappropriate prescriptions in patients with osteoporosis. Expert Review of Endocrinology & Metabolism. [DOI: 10.1080/17446651.2022.2112177] [Reference Citation Analysis]
31 Zhu J, Feng C, Zhang W, Wang Z, Zhong M, Tang W, Wang Z, Shi H, Yin Z, Shi J, Huang Y, Xiao L, Geng D, Wang Z. Activation of dopamine receptor D1 promotes osteogenic differentiation and reduces glucocorticoid-induced bone loss by upregulating the ERK1/2 signaling pathway. Mol Med 2022;28. [DOI: 10.1186/s10020-022-00453-0] [Reference Citation Analysis]
32 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
33 Yu CY, Kuo CF, Chou IJ, Chen JS, Lu HY, Wu CY, Chen LC, Huang JL, Yeh KW. Comorbidities of systemic lupus erythematosus prior to and following diagnosis in different age-at-onset groups. Lupus 2022;:9612033221100908. [PMID: 35536913 DOI: 10.1177/09612033221100908] [Reference Citation Analysis]
34 Gado M, Baschant U, Hofbauer LC, Henneicke H. Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Front Endocrinol 2022;13:835720. [DOI: 10.3389/fendo.2022.835720] [Reference Citation Analysis]
35 Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary Osteoporosis. Endocr Rev 2021:bnab028. [PMID: 34476488 DOI: 10.1210/endrev/bnab028] [Reference Citation Analysis]
36 Formenti AM, Dalla Volta A, di Filippo L, Berruti A, Giustina A. Effects of Medical Treatment of Prostate Cancer on Bone Health. Trends Endocrinol Metab 2021;32:135-58. [PMID: 33509658 DOI: 10.1016/j.tem.2020.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
37 Kuang MJ, Xing F, Wang D, Sun L, Ma JX, Ma XL. CircUSP45 inhibited osteogenesis in glucocorticoid-induced osteonecrosis of femoral head by sponging miR-127-5p through PTEN/AKT signal pathway: Experimental studies. Biochem Biophys Res Commun 2019;509:255-61. [PMID: 30579595 DOI: 10.1016/j.bbrc.2018.12.116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
38 Coskun Benlidayi I. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2018;38:1975-84. [PMID: 30019224 DOI: 10.1007/s00296-018-4106-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
39 Bravenboer N, Oostlander AE, van Bodegraven AA. Bone loss in patients with inflammatory bowel disease: cause, detection and treatment. Curr Opin Gastroenterol 2021;37:128-34. [PMID: 33332916 DOI: 10.1097/MOG.0000000000000710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Egalini F, Parasiliti Caprino M, Gaggero G, Cappiello V, Giannelli J, Rossetto Giaccherino R, Pagano L, Giordano R. Endocrine Disorders in Autoimmune Rheumatological Diseases: A Focus on Thyroid Autoimmune Diseases and on the Effects of Chronic Glucocorticoid Treatment. Endocrines 2021;2:171-84. [DOI: 10.3390/endocrines2030018] [Reference Citation Analysis]
41 Dhooria S, Sehgal IS, Muthu V, Agarwal R. Treatment of allergic bronchopulmonary aspergillosis: from evidence to practice. Future Microbiol 2020;15:365-76. [PMID: 32286102 DOI: 10.2217/fmb-2019-0276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Sekiya C, Suzuki S, Okui H, Tomiita M, Yamamoto S. Low bone mass following diagnosis of Takayasu's arteritis in an 8-year-old girl. Pediatr Int 2022;64:e15187. [PMID: 35510548 DOI: 10.1111/ped.15187] [Reference Citation Analysis]
43 Tedeschi SK, Kim SC, Guan H, Grossman JM, Costenbader KH. Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71:1141-6. [PMID: 30714690 DOI: 10.1002/art.40818] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
44 Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford) 2020;59:487-94. [PMID: 31970410 DOI: 10.1093/rheumatology/kez664] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
45 Vincze A, Gaál J, Griger Z. Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management. Curr Rheumatol Rep 2021;23:55. [PMID: 34196873 DOI: 10.1007/s11926-021-01016-8] [Reference Citation Analysis]
46 Wang N, Wang H, Chen J, Wang F, Wang S, Zhou Q, Ying J, Huang S, Wang P, Yuan F. ACY‑1215, a HDAC6 inhibitor, decreases the dexamethasone‑induced suppression of osteogenesis in MC3T3‑E1 cells. Mol Med Rep 2020;22:2451-9. [PMID: 32705192 DOI: 10.3892/mmr.2020.11319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Wysham KD, Baker JF, Shoback DM. Osteoporosis and fractures in rheumatoid arthritis. Curr Opin Rheumatol 2021;33:270-6. [PMID: 33651725 DOI: 10.1097/BOR.0000000000000789] [Reference Citation Analysis]
48 Wu X, Zhong JY, Wang G, Xu HJ. Factors relating to bone mineral density in young and middle-aged patients with ankylosing spondylitis. Chin Med J (Engl) 2021;134:2556-63. [PMID: 34653076 DOI: 10.1097/CM9.0000000000001787] [Reference Citation Analysis]
49 Hu Z, Xu S, Lin H, Ni W, Yang Q, Qi J, Du K, Gu J, Lin Z. Prevalence and risk factors for bone loss in Southern Chinese with rheumatic diseases. BMC Musculoskelet Disord 2020;21:416. [PMID: 32605558 DOI: 10.1186/s12891-020-03403-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Asada Y, Takayanagi T, Kawakami T, Tomatsu E, Masuda A, Yoshino Y, Sekiguchi-Ueda S, Shibata M, Ide T, Niimi H, Yaoita E, Seino Y, Sugimura Y, Suzuki A. Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats. Int J Endocrinol 2019;2019:4194853. [PMID: 31772574 DOI: 10.1155/2019/4194853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Caplan L, Hansen KE, Saag KG. Response to the American College of Physicians Osteoporosis Guideline, 2017 Update. Arthritis Rheumatol 2017;69:2097-101. [PMID: 28881479 DOI: 10.1002/art.40305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
52 Lee JH, Wei YJ, Zhou ZY, Hou YM, Wang CL, Wang LB, Wu HJ, Zhang Y, Dai WW. Efficacy of the herbal pair, Radix Achyranthis Bidentatae and Eucommiae Cortex, in preventing glucocorticoid-induced osteoporosis in the zebrafish model. J Integr Med 2022;20:83-90. [PMID: 34810131 DOI: 10.1016/j.joim.2021.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica. Drugs Aging 2019;36:1015-26. [PMID: 31493201 DOI: 10.1007/s40266-019-00705-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
54 Haseltine KN, Chukir T, Smith PJ, Jacob JT, Bilezikian JP, Farooki A. Bone Mineral Density: Clinical Relevance and Quantitative Assessment. J Nucl Med 2021;62:446-54. [PMID: 33310738 DOI: 10.2967/jnumed.120.256180] [Reference Citation Analysis]
55 Lespessailles E, Chapurlat R. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int 2020;31:1829-34. [PMID: 32780152 DOI: 10.1007/s00198-020-05568-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
56 Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. The Lancet Diabetes & Endocrinology 2018;6:445-54. [DOI: 10.1016/s2213-8587(18)30075-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]
57 Tanaka I, Tanaka Y, Soen S, Oshima H. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. J Bone Miner Metab 2021;39:446-55. [PMID: 33211212 DOI: 10.1007/s00774-020-01171-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther 2019;13:2843-52. [PMID: 31616133 DOI: 10.2147/DDDT.S148654] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
59 Weare-Regales N, Hudey SN, Lockey RF. Practical Guidance for Prevention and Management of Glucocorticoid-Induced Osteoporosis for the Allergist/Immunologist. J Allergy Clin Immunol Pract 2021;9:1841-50. [PMID: 33444813 DOI: 10.1016/j.jaip.2020.12.050] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Liu Y, Carrino JA, Dash AS, Chukir T, Do H, Bockman RS, Hughes AP, Press JM, Stein EM. Lower Spine Volumetric Bone Density in Patients With a History of Epidural Steroid Injections. J Clin Endocrinol Metab 2018;103:3405-10. [PMID: 29982535 DOI: 10.1210/jc.2018-00558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
61 Moon J, Sin DD. Inhaled corticosteroids and fractures in chronic obstructive pulmonary disease: current understanding and recommendations. Current Opinion in Pulmonary Medicine 2019;25:165-72. [DOI: 10.1097/mcp.0000000000000554] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Miyama A, Ebina K, Hirao M, Okamura G, Etani Y, Takami K, Goshima A, Miura T, Oyama S, Kanamoto T, Yoshikawa H, Nakata K. Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro. J Bone Miner Metab 2021;39:639-48. [PMID: 33564917 DOI: 10.1007/s00774-021-01206-5] [Reference Citation Analysis]
63 Li J, Yang M, Lu C, Han J, Tang S, Zhou J, Li Y, Ming T, Wang ZJ, Su X. Tuna Bone Powder Alleviates Glucocorticoid‐Induced Osteoporosis via Coregulation of the NF‐κB and Wnt/β‐Catenin Signaling Pathways and Modulation of Gut Microbiota Composition and Metabolism. Mol Nutr Food Res 2020;64:1900861. [DOI: 10.1002/mnfr.201900861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
64 Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ. [DOI: 10.1136/bmj.m421] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
65 Takahata M, Shimizu T, Yamada S, Yamamoto T, Hasegawa T, Fujita R, Kobayashi H, Endo T, Koike Y, Amizuka N, Todoh M, Okumura JI, Kajino T, Iwasaki N. Bone biopsy findings in patients receiving long-term bisphosphonate therapy for glucocorticoid-induced osteoporosis. J Bone Miner Metab 2022. [PMID: 35333984 DOI: 10.1007/s00774-022-01323-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Kim JW, Jung JY, Kim HA, Suh CH. Anti-Inflammatory Effects of Low-Dose Glucocorticoids Compensate for Their Detrimental Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis. J Clin Med 2021;10:2944. [PMID: 34209074 DOI: 10.3390/jcm10132944] [Reference Citation Analysis]
67 Cheng CH, Chen LR, Chen KH. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. Int J Mol Sci 2022;23:1376. [PMID: 35163300 DOI: 10.3390/ijms23031376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
68 Nordqvist O, Lönnbom Svensson U, Brudin L, Wanby P, Carlsson M. Adherence to risk management guidelines for drugs which cause vitamin D deficiency - big data from the Swedish health system. Drug Healthc Patient Saf 2019;11:19-28. [PMID: 30962725 DOI: 10.2147/DHPS.S188187] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Campbell EJ, Clarke AE, Ramsey-Goldman R. Systemic lupus erythematosus: a case-based presentation of renal, neurologic, and hematologic emergencies. Expert Rev Clin Immunol 2018;14:803-16. [PMID: 30173578 DOI: 10.1080/1744666X.2018.1518132] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Saunders IM, Tan M, Koura D, Young R. Long-term Follow-up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics. Pharmacotherapy 2020;40:808-41. [PMID: 32652612 DOI: 10.1002/phar.2443] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Zaja F, Carpenedo M, Baratè C, Borchiellini A, Chiurazzi F, Finazzi G, Lucchesi A, Palandri F, Ricco A, Santoro C, Scalzulli P. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. Blood Reviews 2020;41:100647. [DOI: 10.1016/j.blre.2019.100647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
72 Ishida T, Yuri H, Nakamura E, Isoda K, Wada Y, Kotani T, Takeuchi T. Low pre-pregnant body mass index is a risk factor for the decrease of postpartum bone mineral density in systemic lupus erythematosus patients received glucocorticoid therapy. Lupus 2022;:9612033221094710. [PMID: 35440212 DOI: 10.1177/09612033221094710] [Reference Citation Analysis]
73 Lee TH, Song YJ, Kim H, Sung YK, Cho SK. Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines. J Bone Metab 2020;27:247-59. [PMID: 33317228 DOI: 10.11005/jbm.2020.27.4.247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
74 Nuti R, Brandi ML, Checchia G, Di Munno O, Dominguez L, Falaschi P, Fiore CE, Iolascon G, Maggi S, Michieli R, Migliaccio S, Minisola S, Rossini M, Sessa G, Tarantino U, Toselli A, Isaia GC. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2019;14:85-102. [PMID: 29948835 DOI: 10.1007/s11739-018-1874-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 17.3] [Reference Citation Analysis]
75 Yu Y, Lv L, Yin SL, Chen C, Jiang S, Zhou PZ. Clivus-involved immunoglobulin G4 related hypertrophic pachymeningitis mimicking meningioma: A case report. World J Clin Cases 2022; 10(18): 6269-6276 [DOI: 10.12998/wjcc.v10.i18.6269] [Reference Citation Analysis]
76 Garvey TD, Koster MJ, Warrington KJ. My Treatment Approach to Giant Cell Arteritis. Mayo Clin Proc 2021;96:1530-45. [PMID: 34088416 DOI: 10.1016/j.mayocp.2021.02.013] [Reference Citation Analysis]
77 Kwon OC, Oh JS, Park MC, Kim YG. Effect of Vitamin D Supplementation on Bone Mineral Density in Rheumatoid Arthritis Patients With Osteoporosis. Front Med (Lausanne) 2020;7:443. [PMID: 32974365 DOI: 10.3389/fmed.2020.00443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Koike H, Nishi R, Ohyama K, Morozumi S, Kawagashira Y, Furukawa S, Mouri N, Fukami Y, Iijima M, Sobue G, Katsuno M. ANCA-Associated Vasculitic Neuropathies: A Review. Neurol Ther 2022. [PMID: 35044596 DOI: 10.1007/s40120-021-00315-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Li L, Yang M, Jin A. COL3A1, COL6A3, and SERPINH1 Are Related to Glucocorticoid-Induced Osteoporosis Occurrence According to Integrated Bioinformatics Analysis. Med Sci Monit 2020;26:e925474. [PMID: 32999266 DOI: 10.12659/MSM.925474] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Raterman HG, Bultink IEM, Lems WF. Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. Drugs 2019;79:1065-87. [DOI: 10.1007/s40265-019-01145-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
81 Bodden J, Sun D, Joseph GB, Huang LW, Andreadis C, Hughes-Fulford M, Lang TF, Link TM. Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures. Osteoporos Int 2021;32:281-91. [PMID: 32803319 DOI: 10.1007/s00198-020-05577-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab 2018;32:759-72. [PMID: 30449553 DOI: 10.1016/j.beem.2018.05.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
83 Nordqvist J, Engdahl C, Scheffler JM, Gupta P, Gustafsson KL, Lagerquist MK, Carlsten H, Islander U. A tissue-selective estrogen complex as treatment of osteoporosis in experimental lupus. Lupus 2022;:9612033211067984. [PMID: 35062848 DOI: 10.1177/09612033211067984] [Reference Citation Analysis]
84 Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 2019;30:1145-56. [DOI: 10.1007/s00198-019-04906-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 24.7] [Reference Citation Analysis]
85 Cai Z, Wang H, Jiang J, Xiao S, Xiao J, He J, Zhao Z, Yin J. Elaborate the Mechanism of Ancient Classic Prescriptions (Erzhi Formula) in Reversing GIOP by Network Pharmacology Coupled with Zebrafish Verification. Evid Based Complement Alternat Med 2022;2022:7019792. [PMID: 35047047 DOI: 10.1155/2022/7019792] [Reference Citation Analysis]
86 Gazitt T, Zisman D, Gardner G. Polymyalgia Rheumatica: a Common Disease in Seniors. Curr Rheumatol Rep 2020;22:40. [PMID: 32562020 DOI: 10.1007/s11926-020-00919-2] [Reference Citation Analysis]
87 Nogués X, Martinez-laguna D. Update on osteoporosis treatment. Medicina Clínica (English Edition) 2018;150:479-86. [DOI: 10.1016/j.medcle.2018.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Mok CC, Tse SM, Chan KL, Ho LY. Estimation of fracture risk by the FRAX tool in patients with systemic lupus erythematosus: a 10-year longitudinal validation study. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210744. [DOI: 10.1177/1759720x221074451] [Reference Citation Analysis]
89 Sun Y, Xiong Y, Meng YL, Santos HO, Athayde FL, de Souza IGO, Yang L. Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials. Growth Horm IGF Res 2021;60-61:101421. [PMID: 34384975 DOI: 10.1016/j.ghir.2021.101421] [Reference Citation Analysis]
90 Iki M, Fujimori K, Nakatoh S, Tamaki J, Ishii S, Okimoto N, Kamiya K, Ogawa S. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan. Bone 2022. [DOI: 10.1016/j.bone.2022.116396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Cox M, Sandler RD, Matucci-Cerinic M, Hughes M. Bone health in idiopathic inflammatory myopathies. Autoimmun Rev 2021;20:102782. [PMID: 33609795 DOI: 10.1016/j.autrev.2021.102782] [Reference Citation Analysis]
92 Hardy J, Haywood A, Rickett K, Sallnow L, Good P. Practice review: Evidence-based quality use of corticosteroids in the palliative care of patients with advanced cancer. Palliat Med 2021;35:461-72. [PMID: 33499759 DOI: 10.1177/0269216320986717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Chalitsios CV, Shaw DE, McKeever TM. A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England. NPJ Prim Care Respir Med 2020;30:5. [PMID: 32054843 DOI: 10.1038/s41533-020-0162-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
94 Runowska M, Majewski D, Majewska K, Puszczewicz M. Vitamin D supply in patients with rheumatic diseases in Poland - a pilot study. Reumatologia 2021;59:146-52. [PMID: 34538941 DOI: 10.5114/reum.2021.107430] [Reference Citation Analysis]
95 Ishida T, Yoshida S, Fujiki Y, Hata K, Kotani T, Takeuchi T. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study. Arch Osteoporos 2021;16:39. [PMID: 33624165 DOI: 10.1007/s11657-021-00899-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Noh JY, Yang Y, Jung H. Molecular Mechanisms and Emerging Therapeutics for Osteoporosis. Int J Mol Sci 2020;21:E7623. [PMID: 33076329 DOI: 10.3390/ijms21207623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
97 Kocijan R, Klaushofer K, Misof BM. Osteoporosis Therapeutics 2020. Handb Exp Pharmacol 2020;262:397-422. [PMID: 32767142 DOI: 10.1007/164_2020_373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
98 Naranjo Hernández A, Díaz del Campo Fontecha P, Aguado Acín MP, Arboleya Rodríguez L, Casado Burgos E, Castañeda S, Fiter Aresté J, Gifre L, Gómez Vaquero C, Candelas Rodríguez G, Francisco Hernández FM, Guañabens Gay N. Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis. Reumatología Clínica 2019;15:188-210. [DOI: 10.1016/j.reuma.2018.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
99 Hu K, Adachi JD. Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metab 2019;14:259-66. [PMID: 31094232 DOI: 10.1080/17446651.2019.1617131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
100 Gianella F, Hsia CC, Sakhaee K. The role of vitamin D in sarcoidosis. Fac Rev 2020;9:14. [PMID: 33659946 DOI: 10.12703/b/9-14] [Reference Citation Analysis]
101 Dunn P, Webb D, Olenginski TP. Geisinger high-risk osteoporosis clinic (HiROC): 2013-2015 FLS performance analysis. Osteoporos Int 2018;29:451-7. [PMID: 29063214 DOI: 10.1007/s00198-017-4270-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
102 Chen Y, Liu R, Hettinghouse A, Wang S, Liu G, Liu CJ. Clinical Application of Teriparatide in Fracture Prevention: A Systematic Review. JBJS Rev 2019;7:e10. [PMID: 30694878 DOI: 10.2106/JBJS.RVW.18.00052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
103 Tanaka Y. Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. J Clin Med 2021;10:1241. [PMID: 33802804 DOI: 10.3390/jcm10061241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Li L, Xie H, Lu N, Esdaile JM, Aviña-Zubieta JA. Impact of Systemic Lupus Erythematosus on the Risk of Newly Diagnosed Hip Fracture: A General Population-Based Study. Arthritis Care Res (Hoboken) 2021;73:259-65. [PMID: 31758639 DOI: 10.1002/acr.24112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
105 Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Wen A, Cheng W, Dobransky J, Sanger S, Grammatopoulos G. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology 2021;60:649-57. [DOI: 10.1093/rheumatology/keaa228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
106 Nogués X, Martinez-Laguna D. Update on osteoporosis treatment. Med Clin (Barc) 2018;150:479-86. [PMID: 29179892 DOI: 10.1016/j.medcli.2017.10.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
107 Ding L, Hu J, Wang D, Liu Q, Mo Y, Tan X, Wen F. Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures. The Journal of Clinical Endocrinology & Metabolism 2020;105:600-13. [DOI: 10.1210/clinem/dgz023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
108 Anastasilakis AD, Tsourdi E, Makras P, Polyzos SA, Meier C, McCloskey EV, Pepe J, Zillikens MC. Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. Bone 2019;127:401-18. [PMID: 31299385 DOI: 10.1016/j.bone.2019.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
109 Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. J Med Econ 2018;21:846-52. [PMID: 29741439 DOI: 10.1080/13696998.2018.1474750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
110 Ward IM, Knott A. Practical Pearls About Current Rheumatic Medications. Prim Care 2018;45:193-212. [PMID: 29759120 DOI: 10.1016/j.pop.2018.02.003] [Reference Citation Analysis]
111 Adami G, Fassio A, Rossini M, Caimmi C, Giollo A, Orsolini G, Viapiana O, Gatti D. Osteoporosis in Rheumatic Diseases. Int J Mol Sci 2019;20:E5867. [PMID: 31766755 DOI: 10.3390/ijms20235867] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
112 Nakayama M, Furuya T, Inoue E, Tanaka E, Ikari K, Taniguchi A, Yamanaka H, Harigai M. Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: Results from the Institute of Rheumatology Rheumatoid Arthritis cohort study. Osteoporos Sarcopenia 2020;6:82-7. [PMID: 32715099 DOI: 10.1016/j.afos.2020.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
113 Gao Y, Zhu H, Wang Q, Feng Y, Zhang C. Inhibition of PERK Signaling Prevents Against Glucocorticoid-induced Endotheliocyte Apoptosis and Osteonecrosis of the Femoral Head. Int J Biol Sci 2020;16:543-52. [PMID: 32025204 DOI: 10.7150/ijbs.35256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
114 Cho SK, Sung YK. Update on Glucocorticoid Induced Osteoporosis. Endocrinol Metab (Seoul) 2021;36:536-43. [PMID: 34107602 DOI: 10.3803/EnM.2021.1021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Sood V, Rogers L, Khurana S. How I Do It: Managing Corticosteroid-Related Comorbidities in Severe Asthma. Chest 2021:S0012-3692(21)00948-X. [PMID: 34019864 DOI: 10.1016/j.chest.2021.05.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Nordqvist J, Lagerquist MK, Grahnemo L, Koskela A, Islander U, Carlsten H. Osteoporosis in a murine model of postmenopausal lupus. Lupus 2020;29:58-66. [PMID: 31825765 DOI: 10.1177/0961203319893759] [Reference Citation Analysis]
117 Mazziotti G, Vena W, Pedersini R, Piccini S, Morenghi E, Cosentini D, Zucali P, Torrisi R, Sporeni S, Simoncini EL, Maroldi R, Balzarini L, Lania AG, Berruti A. Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice. Journal of Bone Oncology 2022. [DOI: 10.1016/j.jbo.2022.100421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Frara S, Allora A, di Filippo L, Formenti AM, Loli P, Polizzi E, Tradati D, Ulivieri FM, Giustina A. Osteopathy in mild adrenal Cushing's syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab 2021;35:101515. [PMID: 33795196 DOI: 10.1016/j.beem.2021.101515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Li J, Ho WTP, Liu C, Chow SK, Ip M, Yu J, Wong HS, Cheung WH, Sung JJY, Wong RMY. The role of gut microbiota in bone homeostasis. Bone Joint Res 2021;10:51-9. [PMID: 33448869 DOI: 10.1302/2046-3758.101.BJR-2020-0273.R1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
120 Terrier B, Darbon R, Durel CA, Hachulla E, Karras A, Maillard H, Papo T, Puechal X, Pugnet G, Quemeneur T, Samson M, Taille C, Guillevin L; Collaborators. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). Orphanet J Rare Dis 2020;15:351. [PMID: 33372616 DOI: 10.1186/s13023-020-01621-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
121 Mok CC. Osteoporosis in Rheumatic Diseases. Journal of Clinical Rheumatology and Immunology 2022;22:40-7. [DOI: 10.1142/s2661341722300026] [Reference Citation Analysis]
122 Nusbaum JS, Mirza I, Shum J, Freilich RW, Cohen RE, Pillinger MH, Izmirly PM, Buyon JP. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. Mayo Clin Proc 2020;95:384-94. [PMID: 32029091 DOI: 10.1016/j.mayocp.2019.09.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
123 Fields SD, Tung E. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review. Infect Dis Ther 2021;10:165-86. [PMID: 33569743 DOI: 10.1007/s40121-020-00384-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
124 Taulaigo AV, Moschetti L, Ganhão S, Gerardi MC, Franceschini F, Tincani A, Andreoli L. Safety considerations when using drugs in pregnant patients with systemic lupus erythematosus. Expert Opin Drug Saf 2021;20:523-36. [PMID: 33599570 DOI: 10.1080/14740338.2021.1893298] [Reference Citation Analysis]
125 Patel NJ, Stone JH. Expert Perspective: Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 2022. [PMID: 35289109 DOI: 10.1002/art.42114] [Reference Citation Analysis]
126 Lv F, Guan Y, Ma D, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X, Li M. Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment. Clin Endocrinol 2018;88:380-7. [DOI: 10.1111/cen.13537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
127 Nozawa T, Bell-Peter A, Doria AS, Marcuz JA, Stimec J, Whitney K, Feldman BM. Tibia stress injury and the imaging appearance of stress fracture in juvenile dermatomyositis: six patients' experiences. Pediatr Rheumatol Online J 2021;19:17. [PMID: 33596941 DOI: 10.1186/s12969-021-00501-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Gerke AK. Treatment of Sarcoidosis: A Multidisciplinary Approach. Front Immunol 2020;11:545413. [PMID: 33329511 DOI: 10.3389/fimmu.2020.545413] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Doolittle ML, Calabrese GM, Mesner LD, Godfrey DA, Maynard RD, Ackert-Bicknell CL, Farber CR. Genetic analysis of osteoblast activity identifies Zbtb40 as a regulator of osteoblast activity and bone mass. PLoS Genet 2020;16:e1008805. [PMID: 32497039 DOI: 10.1371/journal.pgen.1008805] [Reference Citation Analysis]
130 Yu S, Chen M, Chen J, Wang Y, Chen Y, Hsu C, Lai H, Chiu W, Ko C, He H, Cheng T. Establishment of a preliminary FRAX®-based intervention threshold for rheumatoid arthritis–associated fragility fracture: a 3-year longitudinal, observational, cohort study. Therapeutic Advances in Chronic Disease 2022;13:204062232210780. [DOI: 10.1177/20406223221078089] [Reference Citation Analysis]
131 Salvador F. ANCA associated vasculitis. Eur J Intern Med 2020;74:18-28. [PMID: 32005600 DOI: 10.1016/j.ejim.2020.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
132 Baech J, Hansen SM, Jakobsen LH, Øvlisen AK, Severinsen MT, Brown PDN, Vestergaard P, Frederiksen H, Jørgensen J, Starklint J, Josefsson P, Hammer T, Clausen MR, Torp-pedersen C, Jensen P, El-galaly TC. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leukemia & Lymphoma 2020;61:1345-54. [DOI: 10.1080/10428194.2020.1723015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
133 Nasomyont N, Keefe C, Tian C, Hornung L, Khoury J, Tilden JC, Hochwalt P, Jackson E, Rybalsky I, Wong BL, Rutter MM. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporos Int 2020;31:2449-59. [PMID: 32676823 DOI: 10.1007/s00198-020-05549-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Chotiyarnwong P, Harvey NC, Johansson H, Liu E, Lorentzen M, Kanis JA, McCloskey EV. Temporal changes in access to FRAX® in Thailand between 2010 and 2018. Arch Osteoporos 2019;14:66. [PMID: 31227921 DOI: 10.1007/s11657-019-0613-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
135 Kim SW, Kim EH, Lee J, Choi YC, Kim SM, Shin HY. Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study. Sci Rep 2019;9:9131. [PMID: 31235735 DOI: 10.1038/s41598-019-45591-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Huapaya J, Wiley K, Danoff S. Treatment in Antisynthetase Syndrome-Associated Interstitial Lung Disease. Curr Treat Options in Rheum 2021;7:243-57. [DOI: 10.1007/s40674-021-00177-y] [Reference Citation Analysis]
137 Yoo BW, Jung SM, Song JJ, Park YB, Lee SW. Prevalence of Osteopenia in Drug-Naive Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Monocentric Study. J Clin Rheumatol 2021;27:e330-5. [PMID: 32530864 DOI: 10.1097/RHU.0000000000001413] [Reference Citation Analysis]
138 Muñoz-Torres M, Aguado P, Daudén E, Carrascosa JM, Rivera R. Osteoporosis and Psoriasis. Actas Dermosifiliogr (Engl Ed) 2019;110:642-52. [PMID: 31151668 DOI: 10.1016/j.ad.2019.02.005] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
139 Eyre TA, Jensen P, Booth S, El-Galaly TC. Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures. Br J Haematol 2022. [PMID: 35235226 DOI: 10.1111/bjh.18104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Pacharne S, Livesey M, Kadmiel M, Wang N, Caron KM, Richards GO, Skerry TM. Accelerated Development With Increased Bone Mass and Skeletal Response to Loading Suggest Receptor Activity Modifying Protein-3 as a Bone Anabolic Target. Front Endocrinol 2022;12:807882. [DOI: 10.3389/fendo.2021.807882] [Reference Citation Analysis]
141 Tanaka I, Tanaka Y, Soen S, Oshima H. Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study. Mod Rheumatol 2021:roab034. [PMID: 34910192 DOI: 10.1093/mr/roab034] [Reference Citation Analysis]
142 Iolascon G, de Sire A, Curci C, Paoletta M, Liguori S, Calafiore D, Gimigliano F, Moretti A. Osteoporosis guidelines from a rehabilitation perspective: systematic analysis and quality appraisal using AGREE II. Eur J Phys Rehabil Med 2021;57:273-9. [PMID: 33650841 DOI: 10.23736/S1973-9087.21.06581-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
143 Hayes KN, Baschant U, Hauser B, Burden AM, Winter EM. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis. Front Endocrinol 2021;12:782118. [DOI: 10.3389/fendo.2021.782118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
144 Lee KA, Kim J, Kim HJ, Kim HS. Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid. Int J Rheum Dis 2021;24:1053-60. [PMID: 34184827 DOI: 10.1111/1756-185X.14164] [Reference Citation Analysis]
145 Nguyen Y, Sigaux J, Letarouilly JG, Sanchez P, Czernichow S, Flipo RM, Soubrier M, Semerano L, Seror R, Sellam J, Daïen C. Efficacy of Oral Vitamin Supplementation in Inflammatory Rheumatic Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2020;13:E107. [PMID: 33396851 DOI: 10.3390/nu13010107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
146 Pope R, Doback J. Osteoporosis Diagnosis and Management. Physician Assistant Clinics 2021;6:111-33. [DOI: 10.1016/j.cpha.2020.09.009] [Reference Citation Analysis]
147 Heinlen L, Humphrey MB. Skeletal complications of rheumatoid arthritis. Osteoporos Int 2017;28:2801-12. [PMID: 28779302 DOI: 10.1007/s00198-017-4170-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
148 Laurent MR. Bone: best papers of the year 2017. Arch Osteoporos 2018;13:29. [PMID: 29546647 DOI: 10.1007/s11657-018-0437-5] [Reference Citation Analysis]
149 Adler RA. Glucocorticoid-Induced Osteoporosis and the New ACR Guideline. Clinic Rev Bone Miner Metab 2017;15:123-7. [DOI: 10.1007/s12018-017-9234-8] [Reference Citation Analysis]
150 Sandal R, Mishra K, Jandial A, Sahu KK, Siddiqui AD. Update on diagnosis and treatment of immune thrombocytopenia. Expert Rev Clin Pharmacol 2021;14:553-68. [PMID: 33724124 DOI: 10.1080/17512433.2021.1903315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Lenchik L, Weaver AA, Ward RJ, Boone JM, Boutin RD. Opportunistic Screening for Osteoporosis Using Computed Tomography: State of the Art and Argument for Paradigm Shift. Curr Rheumatol Rep 2018;20:74. [PMID: 30317448 DOI: 10.1007/s11926-018-0784-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
152 Nikas SN. Long-term treatment with low dose glucocorticoids in Rheumatoid Arthritis: New tricks of an old drug. Mediterr J Rheumatol 2018;29:13-6. [PMID: 32185291 DOI: 10.31138/mjr.29.1.13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Galindo-Zavala R, Bou-Torrent R, Magallares-López B, Mir-Perelló C, Palmou-Fontana N, Sevilla-Pérez B, Medrano-San Ildefonso M, González-Fernández MI, Román-Pascual A, Alcañiz-Rodríguez P, Nieto-Gonzalez JC, López-Corbeto M, Graña-Gil J. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J 2020;18:20. [PMID: 32093703 DOI: 10.1186/s12969-020-0411-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
154 Shinoda K, Taki H. Treatment of Glucocorticoid-Induced Osteoporosis and Risk Factors for New Vertebral Fractures in Female Patients with Autoimmune Diseases. J Osteoporos 2021;2021:5515653. [PMID: 34733465 DOI: 10.1155/2021/5515653] [Reference Citation Analysis]
155 Bedatsova L, Drake MT. The skeletal impact of cancer therapies. Br J Clin Pharmacol 2019;85:1161-8. [PMID: 30723928 DOI: 10.1111/bcp.13866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
156 Lupsa BC, Insogna KL, Micheletti RG, Caplan A. Corticosteroid use in chronic dermatologic disorders and osteoporosis. Int J Womens Dermatol 2021;7:545-51. [PMID: 35024411 DOI: 10.1016/j.ijwd.2021.07.014] [Reference Citation Analysis]
157 Salooja N, Greinix H, Ruutu T, van der Werf S, van Biezen A, Lawitschka A, Basak G, Duarte R. Investigation and Management of Bone Mineral Density Following Hematopoietic Cell Transplantation: A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2020;26:1955-62. [PMID: 32623077 DOI: 10.1016/j.bbmt.2020.06.022] [Reference Citation Analysis]
158 Sato H, Kondo N, Wakamatsu A, Kobayashi D, Nakatsue T, Wada Y, Kuroda T, Suzuki Y, Nakano M, Endo N, Narita I. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. Rheumatol Int 2019;39:1803-10. [PMID: 31385078 DOI: 10.1007/s00296-019-04407-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
159 Raterman HG, Lems WF. Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide. Drugs Aging 2019;36:1061-72. [PMID: 31541358 DOI: 10.1007/s40266-019-00714-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
160 Fu L, Wu W, Sun X, Zhang P. Glucocorticoids Enhanced Osteoclast Autophagy Through the PI3K/Akt/mTOR Signaling Pathway. Calcif Tissue Int 2020;107:60-71. [DOI: 10.1007/s00223-020-00687-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
161 Watts NB. Adverse bone effects of medications used to treat non-skeletal disorders. Osteoporos Int 2017;28:2741-6. [PMID: 28752332 DOI: 10.1007/s00198-017-4171-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
162 Tedeschi SK, Aranow C, Kamen DL, LeBoff M, Diamond B, Costenbader KH. Effect of vitamin D on serum markers of bone turnover in SLE in a randomised controlled trial. Lupus Sci Med 2019;6:e000352. [PMID: 31592329 DOI: 10.1136/lupus-2019-000352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
163 Ozen G, Kamen DL, Mikuls TR, England BR, Wolfe F, Michaud K. Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis. Arthritis Care Res (Hoboken) 2018;70:713-23. [PMID: 28771973 DOI: 10.1002/acr.23331] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
164 Andersen NB, Jørgensen NR. Impaired bone health as a co-morbidity of epilepsy. Best Pract Res Clin Rheumatol 2022;:101755. [PMID: 35659828 DOI: 10.1016/j.berh.2022.101755] [Reference Citation Analysis]
165 Galati A, Brown ES, Bove R, Vaidya A, Gelfand J. Glucocorticoids for therapeutic immunosuppression: Clinical pearls for the practicing neurologist. J Neurol Sci 2021;430:120004. [PMID: 34598056 DOI: 10.1016/j.jns.2021.120004] [Reference Citation Analysis]
166 LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2022. [PMID: 35478046 DOI: 10.1007/s00198-021-05900-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
167 Gabelli M, Ademokun C, Cooper N, Amrolia PI. Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting. Br J Haematol 2021. [PMID: 34195990 DOI: 10.1111/bjh.17648] [Reference Citation Analysis]
168 Florez H, Hernández-Rodríguez J, Carrasco JL, Prieto-González S, Muxi A, Filella X, Ruiz-Gaspà S, Gómez-Puerta JA, Cid M, Espinosa G, Monegal A, Guañabens N, Peris P. Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. RMD Open 2020;6:e001355. [PMID: 32917834 DOI: 10.1136/rmdopen-2020-001355] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
169 Huang LW, Sun D, Link TM, Lang T, Ai W, Kaplan LD, Steinman MA, Andreadis C. High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas. Support Care Cancer 2021;29:5399-408. [PMID: 33694088 DOI: 10.1007/s00520-021-06120-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Yoon SB, Moon SH, Kim JH, Park JW, Kim SE, Kim MH. Determination of the duration of glucocorticoid therapy in type 1 autoimmune pancreatitis: A systematic review and meta-analysis. Pancreatology 2021:S1424-3903(21)00474-9. [PMID: 34090808 DOI: 10.1016/j.pan.2021.05.303] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Mok CC, Ho LY, Leung SMT, Cheung HN, Chen SPL, Ma KM. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. Bone 2021;146:115902. [PMID: 33631355 DOI: 10.1016/j.bone.2021.115902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
172 Saketkoo LA, Russell AM, Jensen K, Mandizha J, Tavee J, Newton J, Rivera F, Howie M, Reese R, Goodman M, Hart P, Strookappe B, De Vries J, Rosenbach M, Scholand MB, Lammi MR, Elfferich M, Lower E, Baughman RP, Sweiss N, Judson MA, Drent M. Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel) 2021;11:1089. [PMID: 34203584 DOI: 10.3390/diagnostics11061089] [Reference Citation Analysis]
173 Chiodini I, Falchetti A, Merlotti D, Eller Vainicher C, Gennari L. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. Expert Rev Endocrinol Metab 2020;15:283-98. [PMID: 32584619 DOI: 10.1080/17446651.2020.1772051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
174 Takhar JS, Pawar VK, Marneris AG, Doan TA, Acharya NR, Gonzales JA. When to Consider Bisphosphonates in Patients on Steroids for Chronic Ocular Inflammatory Conditions. J Ocul Pharmacol Ther 2019;35:379-80. [PMID: 31241403 DOI: 10.1089/jop.2019.0058] [Reference Citation Analysis]
175 Yang RZ, Xu WN, Zheng HL, Zheng XF, Li B, Jiang LS, Jiang SD. Exosomes derived from vascular endothelial cells antagonize glucocorticoid-induced osteoporosis by inhibiting ferritinophagy with resultant limited ferroptosis of osteoblasts. J Cell Physiol 2021;236:6691-705. [PMID: 33590921 DOI: 10.1002/jcp.30331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Russell LA. Management of difficult osteoporosis. Best Practice & Research Clinical Rheumatology 2018;32:835-47. [DOI: 10.1016/j.berh.2019.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
177 Adami G, Rahn EJ, Saag KG. Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice. Ther Adv Musculoskelet Dis 2019;11:1759720X19876468. [PMID: 31565078 DOI: 10.1177/1759720X19876468] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
178 Frara S, di Filippo L, Doga M, Loli P, Casanueva FF, Giustina A. Novel approaches to bone comorbidity in Cushing's disease: an update. Pituitary 2022. [PMID: 35849272 DOI: 10.1007/s11102-022-01252-w] [Reference Citation Analysis]
179 Mikdashi J. The Meaningful Role of Patients, and Other Stakeholders in Clinical Practice Guideline Development. Rheumatic Disease Clinics of North America 2022. [DOI: 10.1016/j.rdc.2022.05.002] [Reference Citation Analysis]
180 Park HY, Kim S, Sohn HS, Kwon JW. The Association between Polypharmacy and Hip Fracture in Osteoporotic Women: A Nested Case-Control Study in South Korea. Clin Drug Investig 2019;39:63-71. [PMID: 30306340 DOI: 10.1007/s40261-018-0716-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
181 Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2019;49:251-9. [PMID: 30987856 DOI: 10.1016/j.semarthrit.2019.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
182 Bae HJ. Ventricular Arrhythmia Associated With Magnesium and Vitamin D Deficiencies in a Patient With Rheumatoid Arthritis. Cureus 2021;13:e19143. [PMID: 34868778 DOI: 10.7759/cureus.19143] [Reference Citation Analysis]
183 Gazitt T, Elias M, Feld J, Lavi I, Haddad A, Bishara-Garzuzi R, Elhija MA, Kibari A, Zisman D. Implementation of recommendations for prevention of glucocorticosteroid-induced osteoporosis in hospitalized patients. Clin Rheumatol 2021. [PMID: 34159492 DOI: 10.1007/s10067-021-05820-6] [Reference Citation Analysis]
184 Sapkota HR, Nune A, Bateman J, Venkatachalam S. A pragmatic proposal for triaging DXA testing during the COVID-19 global pandemic. Osteoporos Int 2021;32:1-6. [PMID: 33146750 DOI: 10.1007/s00198-020-05722-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
185 Messina OD, Vidal LF, Wilman MV, Bultink IEM, Raterman HG, Lems W. Management of glucocorticoid-induced osteoporosis. Aging Clin Exp Res 2021;33:793-804. [PMID: 33751462 DOI: 10.1007/s40520-021-01823-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
186 Adami G, Saag KG. Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis. Curr Rheumatol Rep 2019;21. [DOI: 10.1007/s11926-019-0836-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
187 Therkildsen P, de Thurah A, Hansen IT, Nørgaard M, Nielsen BD, Hauge EM. Giant cell arteritis: A nationwide, population-based cohort study on incidence, diagnostic imaging, and glucocorticoid treatment. Semin Arthritis Rheum 2021;51:360-6. [PMID: 33601192 DOI: 10.1016/j.semarthrit.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Ayub N, Faraj M, Ghatan S, Reijers JAA, Napoli N, Oei L. The Treatment Gap in Osteoporosis. J Clin Med 2021;10:3002. [PMID: 34279485 DOI: 10.3390/jcm10133002] [Reference Citation Analysis]
189 Korucu B, Yeter H, Guz G. The Effects of CNI and Mtori-Based Regimens on Bone Mineral Density After Renal Transplantation. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2022;43:101-7. [PMID: 35451298 DOI: 10.2478/prilozi-2022-0010] [Reference Citation Analysis]
190 Iki M, Fujimori K, Nakatoh S, Tamaki J, Ishii S, Okimoto N, Kamiya K, Ogawa S. Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study. Osteoporos Int 2022. [PMID: 35022812 DOI: 10.1007/s00198-021-06265-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Ng JY, Hilal A, Maini I. What traditional, complementary, and integrative medicine recommendations exist across osteoporosis clinical practice guidelines? A systematic review and quality assessment. Integr Med Res 2022;11:100803. [PMID: 34840950 DOI: 10.1016/j.imr.2021.100803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
192 Szekanecz Z, Raterman HG, Pethő Z, Lems WF. Common mechanisms and holistic care in atherosclerosis and osteoporosis. Arthritis Res Ther 2019;21:15. [PMID: 30630495 DOI: 10.1186/s13075-018-1805-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
193 Petta I, Peene I, Elewaut D, Vereecke L, De Bosscher K. Risks and benefits of corticosteroids in arthritic diseases in the clinic. Biochem Pharmacol 2019;165:112-25. [PMID: 30978323 DOI: 10.1016/j.bcp.2019.04.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
194 Chiodini I, Merlotti D, Falchetti A, Gennari L. Treatment options for glucocorticoid-induced osteoporosis. Expert Opin Pharmacother 2020;21:721-32. [PMID: 32004105 DOI: 10.1080/14656566.2020.1721467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
195 Peng Z, Xu R, You Q. Role of Traditional Chinese Medicine in Bone Regeneration and Osteoporosis. Front Bioeng Biotechnol 2022;10:911326. [DOI: 10.3389/fbioe.2022.911326] [Reference Citation Analysis]
196 Domingo Ribas C, Carrillo Díaz T, Blanco Aparicio M, Martínez Moragón E, Banas Conejero D, Sánchez Herrero MG; REDES Study Group. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. Drugs 2021;81:1763-74. [PMID: 34586602 DOI: 10.1007/s40265-021-01597-9] [Reference Citation Analysis]
197 Leipe J, Holle JU, Weseloh C, Pfeil A, Krüger K; die Kommission Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie e. V. (DGRh). [German Society of Rheumatology Recommendations for the management of glucocorticoid-induced Osteoporosis. German version]. Z Rheumatol 2021;80:670-87. [PMID: 34357436 DOI: 10.1007/s00393-021-01028-w] [Reference Citation Analysis]
198 Autore F, Pasquale R, Innocenti I, Fresa A, Sora' F, Laurenti L. Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review. Cancers (Basel) 2021;13:5804. [PMID: 34830959 DOI: 10.3390/cancers13225804] [Reference Citation Analysis]
199 Bowden SA, Mahan JD. Zoledronic acid in pediatric metabolic bone disorders. Transl Pediatr 2017;6:256-68. [PMID: 29184807 DOI: 10.21037/tp.2017.09.10] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
200 Wysham KD, Baker JF, Narla R. Osteoporosis evaluation and treatment recommendations in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2022;:101757. [PMID: 35739049 DOI: 10.1016/j.berh.2022.101757] [Reference Citation Analysis]
201 Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019;96:1-13. [PMID: 30448290 DOI: 10.1016/j.jaut.2018.11.001] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 27.5] [Reference Citation Analysis]